News
CHRS
2.265
+2.03%
0.045
Weekly Report: what happened at CHRS last week (0429-0503)?
Weekly Report · 1d ago
Weekly Report: what happened at CHRS last week (0422-0426)?
Weekly Report · 04/29 10:09
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
First presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, will be presented at the upcoming ASCO Annual Meeting in Chicago. Coherus BioSciences, Inc. Will present the first presentation of data for chs-114.
Barchart · 04/24 09:02
Weekly Report: what happened at CHRS last week (0415-0419)?
Weekly Report · 04/22 10:05
CVS favors Humira copycats hurting AbbVie’s market share: Evercore
Seeking Alpha · 04/17 13:26
Weekly Report: what happened at CHRS last week (0408-0412)?
Weekly Report · 04/15 10:00
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Acadia Healthcare (ACHC) and Coherus Biosciences (CHRS)
TipRanks · 04/15 08:30
AbbVie keeps Humira market share near 100% despite biosimilars: report
Healthcare AbbVie keeps Humira market share near 100% despite biosimilars: report. Humira is the world's bestselling drug for the 10th year in a row. Amgen launched the first biosimilar version of the arthritis drug in the U.S. Last year.
Seeking Alpha · 04/13 14:52
Commit To Purchase Coherus BioSciences At $2, Earn 32.2% Annualized Using Options
NASDAQ · 04/09 15:34
Coherus Presents Preclinical Data For CHS-1000, A Novel Anti-ILT4 Antibody, At The 2024 AACR Annual Meeting
Coherus BioSciences presents preclinical data for its immuno-oncology pipeline candidate, CHS-1000, a novel ILT4 monoclonal antibody. In preclinical studies, CHs-1000 shows a high affinity for human ILt4. Mechanism may enhance antitumor responses with immunotherapy. First novel immunosuppressive cancer product candidate discovered and developed by Coherus. The CHS -1000 IND submission is planned for Q2 2024.
Benzinga · 04/08 12:34
Weekly Report: what happened at CHRS last week (0401-0405)?
Weekly Report · 04/08 10:03
CNDT, CHRS and OM are among materials movers
On the Move CNDT, CHRS and OM are among materials movers. Palladyne, STRC and Conduent are among companies that lost ground. Applied Optoelectronics and Magnite are among the biggest gainers in this week's list.
Seeking Alpha · 04/05 20:42
Weekly Report: what happened at CHRS last week (0325-0329)?
Weekly Report · 04/01 10:02
Weekly Report: what happened at CHRS last week (0318-0322)?
Weekly Report · 03/25 10:04
Coherus Biosciences: Dumping One Drug But Showing Promise With Another
Coherus Biosciences has sold Cimerli, a Lucentis biosimilar, to Sandoz for $170M. CHRS has a new drug and a developmental pipeline. The company's anti-IL-27 antibody, casdozokitug, shows promising results in hepatocellular carcinoma. I upgrade my rating from hold to buy for Coherus.
Seeking Alpha · 03/21 00:14
Coherus BioSciences Price Target Cut to $11.00/Share From $13.00 by HC Wainwright & Co.
Dow Jones · 03/20 11:28
Coherus BioSciences Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/20 11:28
HC Wainwright & Co. Maintains Buy on Coherus BioSciences, Lowers Price Target to $11
Benzinga · 03/20 11:19
Buy Rating on Coherus Biosciences: Balancing Divestiture with Promising Pipeline and Financial Growth
TipRanks · 03/20 10:16
Weekly Report: what happened at CHRS last week (0311-0315)?
Weekly Report · 03/18 10:03
More
Webull provides a variety of real-time CHRS stock news. You can receive the latest news about Coherus Bioscien through multiple platforms. This information may help you make smarter investment decisions.
About CHRS
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. Its immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an anti-IL-27 antibody being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is an ADCC-enhanced anti-CCR8 antibody in a Phase I/II study as a monotherapy in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a next generation PD-1 inhibitor, UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta, and YUSIMRY (adalimumab-aqvh), a biosimilar of Humira.